Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Constellation Energy Corporation (CEG) vs Eli Lilly And Co (LLY) Price & Performance

Constellation Energy CorporationTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Constellation Energy Corporation vs Eli Lilly And Co — how do they compare? Constellation Energy Corporation trades at $257.84 (market cap $91.57B), while Eli Lilly And Co trades at $1,152.5 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 11.2× Constellation Energy Corporation's market cap, and Constellation Energy Corporation pays the higher dividend (0.67%). Which is the better fit depends on your goals.

CEGLLY
Market Cap
$91.57B$1.03T
Sector
EnergyHealth
52-Week High
$403.95$1.24K
52-Week Low
$236.50$625.65
Enterprise Value
$113.24B$1.07T
Dividend Yield
0.67%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Constellation Energy Corporation

Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.

The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

Read more on CEG

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY